SELLAS Life Sciences Group Inc. (SLS)
NASDAQ: SLS · Pharmaceutical Preparations · New York, NY
Our rating: Cautious
Cautious reaffirmed at $14.86, moderate conviction, November 19, 2026.
Breaks if: The Cautious call is wrong if SELLAS announces a successful pivotal-trial readout for its lead pipeline asset and either files for FDA approval or closes a licensing partnership that generates at least $30M in contractually committed forward revenue within the next 12 months — either of which would bridge the current zero-revenue reality to a commercially credible franchise. A sustained close above $22 (roughly 50% above today's price) driven by confirmed clinical or regulatory news would signal the market has priced a catalyst this analysis underweighted.
Key figures
| Market value | $2.8B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$36M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −40.3% |
| Beta to the S&P 500 | 0.87 |
| Volatility, annualized | 136.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $0.00 | n/a | $-0.05 | n/a |
| June 30, 2026 | n/a | n/a | $-0.05 | n/a |
| March 31, 2026 | n/a | n/a | $-0.05 | n/a |
| December 31, 2025 | n/a | n/a | $-0.05 | n/a |
| September 30, 2025 | $0.00 | n/a | $-0.06 | n/a |
| June 30, 2025 | n/a | n/a | $-0.07 | n/a |
| March 31, 2025 | n/a | n/a | $-0.07 | n/a |
| December 31, 2024 | n/a | n/a | $-0.08 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 4%, Gemini 5%, Mistral 2%
34 ledger entries and 140 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.